Common bacteria cause some colon tumors by altering peroxide-producing gene

November 04, 2011

Working with lab cultures and mice, Johns Hopkins scientists have found that a strain of the common gut pathogen Bacteroides fragilis causes colon inflammation and increases activity of a gene called spermine oxidase (SMO) in the intestine. The effect is to expose the gut to hydrogen peroxide - the caustic, germ-fighting substance found in many medicine cabinets -- and cause DNA damage, contributing to the formation of colon tumors, say the scientists.

"Our data suggest that the SMO gene and its products may be one of the few good targets we have discovered for chemoprevention," says Robert Casero, Ph.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center.

In a study, Casero and his colleagues introduced B. fragilis to two colon cell lines and measured SMO gene activity. In both cell lines, SMO gene activity increased two to four times higher than cells not exposed to the bacteria. The scientists also observed similar increases in enzymes produced by the SMO gene. The scientists successfully prevented DNA damage in these cells by blocking SMO enzyme activity with a compound called MDL 72527.

The Johns Hopkins team also tested their observations in a mouse model, created by Hopkins infectious disease specialist Cynthia Sears, M.D., to develop colon tumors. Mice exposed to the bacteria had similar increases in SMO. Mice treated with MDL 72527 had far fewer tumors and lower levels of colon inflammation than untreated mice. Results of the experiments were published online in the Proceedings of the National Academy of Sciences in August.

Casero says hydrogen peroxide can freely distribute through and into other cells. "It roams around, and can damage the DNA in cells," he says.

Rising levels of hydrogen peroxide and DNA damage in the colon are clear steps to tumor development, says Andrew Goodwin, Ph.D., who spearheaded the studies while performing graduate work in Johns Hopkins' Cellular and Molecular Medicine Program and Casero's laboratory.

B. fragilis strains that secrete a toxin are widely known to cause diarrhea in children and adults, and previous studies, including those at Johns Hopkins, have linked the toxin-producing bacteria to inflammation and colon cancer. Casero and collaborators previously linked the SMO gene to inflammation and cancer of the prostate and stomach.

Using MDL 72527 in humans is not advised, Casero says, because the compound blocks another enzyme in addition to SMO. Investigators hope to develop a drug that targets only the SMO enzyme. Candidates for such prevention strategies may include people with a history of colon polyps, which increases risk for colon cancer, and those with inflammatory bowel disease.
-end-
Funding for the research was provided by the Samuel Waxman Cancer Research Foundation and the National Institutes of Health.

In addition to Casero, Goodwin and Sears, other scientists who contributed to the research include Christina E. Destefano Shields, Shaoguang Wu, David L. Huso, XinQun Wu, Tracy R. Murray-Stewart, Amy Hacker Prietz, and Shervin Rabizadeh at Johns Hopkins; and Patrick M. Woster from the Medical University of South Carolina.

DOI: 10.1073/pnas.1010203108

Related News Release:
How Diarrheal Bacteria Causes Some Colon Cancers:
http://www.hopkinsmedicine.org/news/media/releases/How_Diarrheal_Bacteria_Causes_Some_Colon_Cancers

On the Web:
http://www.hopkinskimmelcancercenter.org

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.